We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults.
- Authors
Rennert, Lior; Ma, Zichen; McMahan, Christopher S.; Dean, Delphine
- Abstract
Data on effectiveness and protection duration of Covid-19 vaccines and previous infection against general SARS-CoV-2 infection in general populations are limited. Here we evaluate protection from Covid-19 vaccination (primary series) and previous infection in 21,261 university students undergoing repeated surveillance testing between 8/8/2021–12/04/2021, during which B.1.617 (delta) was the dominant SARS-CoV-2 variant. Estimated mRNA-1273, BNT162b2, and AD26.COV2.S effectiveness against any SARS-CoV-2 infection is 75.4% (95% CI: 70.5-79.5), 65.7% (95% CI: 61.1-69.8), and 42.8% (95% CI: 26.1–55.8), respectively. Among previously infected individuals, protection is 72.9% when unvaccinated (95% CI: 66.1–78.4) and increased by 22.1% with full vaccination (95% CI: 15.8–28.7). Statistically significant decline in protection is observed for mRNA-1273 (P <.001), BNT162b2 (P <.001), but not Ad26.CoV2.S (P = 0.40) or previous infection (P = 0.12). mRNA vaccine protection dropped 29.7% (95% CI: 17.9–41.6) six months post- vaccination, from 83.2% to 53.5%. We conclude that the 2-dose mRNA vaccine series initially offers strong protection against general SARS-CoV-2 infection caused by the delta variant in young adults, but protection substantially decreases over time. These findings indicate that vaccinated individuals may still contribute to community spread. While previous SARS-CoV-2 infection consistently provides moderately strong protection against repeat infection from delta, vaccination yields a substantial increase in protection. Here the authors estimate effectiveness of three COVID-19 vaccines in university students and find that 2-dose mRNA vaccines offer strong protection against general SARS-CoV-2 infection caused by delta, but protection substantially declines over 6 months. While previous infection protects against reinfection, vaccination substantially increases protection.
- Subjects
COVID-19 vaccines; YOUNG adults; SARS-CoV-2; SARS-CoV-2 Delta variant; INFECTIOUS disease transmission; INFECTION
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-31469-z